This article was last reviewed on
This article waslast modified on November 27, 2017.
What is Osteoporosis?

Bone is a living tissue that is constantly being broken down and rebuilt. When the balance between breakdown and rebuilding is disturbed – for example, by hormonal changes or dietary changes – the bone may lose some of the minerals that contribute to its density and strength. A condition of diminished bone density is called osteopenia. When a significant loss in bone density occurs, such that the bone is markedly weakened and susceptible to fracture, the condition is termed osteoporosis (porous bone).

Osteoporosis increases the risk of bone fractures, especially in the hips, spine, and wrists. Although it can affect anyone, the risk of developing osteoporosis increases with age, affects women significantly more often than men, and is most prevalent in Caucasian and Asian women. According to the National Osteoporosis Foundation (NOF), 10 million people in the United States have osteoporosis and another 43 million have low bone mass and are at risk of developing the disease. Of those who have osteoporosis, 80% are women. Risk is also higher in individuals with petite body frames who likely have a lower than average bone mass supply.

Most of the people at risk for osteoporosis are not aware of it. It is called a "silent disease" because there are usually no symptoms until a person has a bone fracture. This breakage, frequently in the hip, the vertebrae of the spine, or in the wrist, can occur with very little pressure and can cause the person significant pain and protracted or permanent disability. If the fracture causes severe debility and affects the person's general health, it may be a contributing factor in the person's death.

Bones are primarily a combination of type-I collagen protein and calcium phosphate. The protein forms a spongy network that is "mineralized" by the addition of the calcium compound to make the bones both strong and flexible. Bone is living tissue that is slowly but continuously replaced. During a process called bone resorption, cells called osteoclasts dissolve bone on a microscopic scale and enzymes break down the collagen network. This is followed by the formation of new bone by cells called osteoblasts. This on-going process is called bone turnover or bone remodeling and continues throughout a person's life. An individual's entire skeleton is replaced about every 10 years.

During childhood, bone formation proceeds at a faster rate than bone resorption and bone mass increases to peak usually by the early 20's. After this peak, bone formation slows and resorption begins to outpace it, resulting in a decline in bone mass with age. Calcium and vitamin D deficiencies during childhood, the use of medications that contain high-dose glucocorticosteroids (although not the usual doses taken as inhalers to control asthma or nasal allergies), eating disorders (e.g., anorexia), gastrointestinal surgery, inactivity, smoking, and excess alcohol consumption can all increase the risk of a person developing osteoporosis later in life. Some diseases, such as thyroid disease, Cushing disease, rheumatoid arthritis, kidney disease, and hyperparathyroidism, can also have an effect on bone health. Those with a strong family history of osteoporosis may also be at an increased risk of developing it.

Menopausal and postmenopausal women may experience an increased rate of bone mass loss with a decrease in the hormone estrogen. Going through menopause early can exacerbate the loss. According to the NOF, some women can lose up to 20% of their bone mass in the first 5 to 7 years following menopause. Men with decreased testosterone levels are also at risk for increased bone loss.

There are two types of osteoporosis:

Primary- or age-related osteoporosis. This refers to osteoporosis developing without any apparent cause. It is much more common in women but can also be seen in men, particularly in older men. As mentioned earlier, in some women the rate of bone loss is very high right after menopause and fractures can occur at a relatively early age, but in most women osteoporosis does not cause fractures until they are in their 60's or 70's. Most common are spine compression fractures. Changes in lifestyle, calcium, or vitamin D supplements or other medications that decrease bone loss may slow the progression of this type of osteoporosis.

Secondary-osteoporosis. This refers to bone loss due to another disease. It affects both men and women and may be due to several different disorders, including rheumatoid arthritis, hyperparathyroidism, Cushing disease, chronic kidney disease, multiple myeloma, or drugs such as anti-epileptics, glucocorticoids, or lithium. Treatment of the underlying disease or cause may slow the loss of bone density in secondary osteoporosis.

 

Accordion Title
About Osteoporosis
  • Tests

    The goals with testing are to determine whether a person has osteoporosis, has low bone mass and an increased risk of developing the disease, is menopausal and/or hormone-deficient, and/or has an underlying condition that may be causing or exacerbating bone loss. Testing may be done to screen for bone density loss or to evaluate bone status when a person has an unexpected bone fracture and may be used to monitor osteoporosis therapy for effectiveness.

    Several organizations have published guidelines on screening for osteoporosis, including the American College of Obstetricians and Gynecologists (ACOG), National Osteoporosis Foundation (NOF), and the U.S. Preventive Services Task Force (USPSTF), which recommend screening for all women beginning at age 65 and, in some cases, younger women based on risk factors. The NOF also recommends screening men age 70 and older as well as those age 50 to 69 with risk factors.

    Non-laboratory tests
    The bone mineral density (BMD) test is the primary test used to identify osteoporosis and low bone mass. One of the preferred and most accurate ways to measure BMD is Dexa-Scan (dual-energy X-ray absorptiometry or DXA). It uses a low energy X-ray to evaluate bone density in the hip and/or spine. BMD is often reported in terms of peak bone mass in young adults. A BMD value that is less than 1 standard deviation below the young adult mean is considered normal. BMD in osteopenia has a value between -1 and -2.5 standard deviations below the young adult mean while osteoporosis BMD values are even lower and are at least -2.5 standard deviations below the mean.

    A healthcare practitioner can now also use a calculator, called the FRAX tool, to better determine a person's risk of a hip, wrist, shoulder, or spine fracture after age 40. Available online or on paper, the calculator, developed by the World Health Organization, considers a person's bone mineral density measurement and a number of other risk factors. It is an algorithm for estimating 10-year probability of fracture. The NOF has adapted this algorithm for the U.S. and its Clinician's Guide released in February 2008 applies it.

    Portable BMD screening devices, utilized at some pharmacies, health fairs, etc., are used to scan people's heels or fingers. These scans are not as accurate as the DXA but may be used as an initial scan. When these tests show decreased bone density, a DXA scan may be performed for confirmation.

    Other diagnostic imaging tests that may be done to measure BMD and to detect osteoporosis include CT scans (computerized tomography), X-rays, and ultrasounds. A general screening test called "body composition analysis" can determine a person's percentages of body weight due to muscle, fat, bone, and water. There are a few different ways to measure body composition, including the use of specialized instruments. If body composition analysis is performed and results tracked from year to year, it may be able to help detect bone loss.

    One other diagnostic imaging test used to evaluate the condition of the bones is a bone scan, which is not to be confused with the bone density scan or BMD. While the BMD test is used to identify low bone density that is indicative of osteoporosis and is non-invasive, a bone scan is a nuclear medicine test used to rule out other serious conditions of the bones. To perform this test, a radioactive tracer is injected into a vein in the arm. The tracer then travels through the blood and is absorbed by the bones. The level of radioactivity detected in the bone is evaluated and can point to conditions or diseases such as metastatic cancer, infection, causes of unexplained bone pain, or Paget's disease. This type of scan can discover problems with the bones much earlier than a regular X-ray and may be ordered when someone has a high frequency of bone fractures.

    Laboratory tests
    Blood tests that may be ordered include:


    Bone markers are blood and urine tests that may sometimes be ordered to help evaluate and monitor the rate of bone resorption and formation. They are not used for diagnosis. 

    Tests measuring bone loss (Bone resorption markers)
    Bone resorption tests tell about the rate of bone loss. They can be checked before treatment and again after treatment to see if the rate of bone loss has decreased. They include:

    • C-telopeptide (C-terminal telopeptide of type 1 collagen (CTx))
    • Urinary collagen type 1 cross-linked N-telopeptide (NTX)
    • Deoxypyridinoline (DPD)
    • Pyridinium Crosslinks
    • Urinary hydroxyproline
    • Tartrate-resistant acid phosphatase (TRAP) 5b
    • Bone sialoprotein (BSP)


    Tests measuring bone formation (Bone formation markers)
    Bone formation tests tell about the rate of bone production. As with bone turnover tests, they may be checked before the start of treatment and periodically after treatment to see if bone formation has increased. They include:

    • Bone-specific alkaline phosphatase (ALP)
    • Osteocalcin (bone gla protein)
    • Procollagen Type 1 N-Terminal Propeptide (P1NP) and C-terminal (C1NP)


    For more detailed information on these tests, see the article on Bone Markers.

  • Treatment and Prevention

    The best treatment for osteoporosis is prevention. While preventive measures cannot eliminate every case of osteoporosis, regular weight-bearing exercise (such as walking and resistance training), eating foods rich in calcium and vitamin D (and supplements as needed), quitting smoking, and moderating alcohol consumption can all help reduce the risk. The American College of Obstetricians and Gynecologists (ACOG) in a recent practice bulletin outlines recommended age-appropriate dietary allowances for vitamin D and calcium that women should take on a daily basis. To maintain healthy bones, a woman should have a vitamin D level of at least 20 nanograms per milliliter (ng/mL). The sooner these lifestyle measures are adopted, the more that they can help. Maximizing bone mass in the young and minimizing bone loss during aging can help prevent or minimize osteoporosis.

    For those at increased risk of osteoporosis, those who have decreased bone mass, and those who have been diagnosed with osteoporosis (and who may have already experienced a bone fracture), there are a variety of treatments available, including antiresorptive medications and bone forming (anabolic) medications. They are used to help inhibit bone resorption, increase bone formation, maintain bone mass, and reduce the number of fractures. Some examples include bisphosphonates, estrogen, estrogen agonists/antagonists (also called selective estrogen receptor modulators or SERMS), calcitonin, and parathyroid hormone.

    People with osteoporosis should work with their healthcare providers to determine which treatments are right for them as well as adopt lifestyle changes that will help them conserve bone mass and take measures to prevent falling, a common cause of osteoporosis-related fractures. Those who take medications that can cause bone density loss, such as prednisone or other glucocorticoids, and some anticonvulsant drugs should talk to their healthcare providers about their alternatives. It is important that they do this prior to stopping any medications.

View Sources

NOTE: This article is based on research that utilizes the sources cited here as well as the collective experience of the Lab Tests Online Editorial Review Board. This article is periodically reviewed by the Editorial Board and may be updated as a result of the review. Any new sources cited will be added to the list and distinguished from the original sources used. To access online sources, copy and paste the URL into your browser.

Sources Used in Current Review

(June 2, 2014) National Osteoporosis Foundation. Updated prevalence data. Available online at https://www.nof.org/2014/06/02/54-million-americans-affected-by-osteoporosis-and-low-bone-mass/. Accessed June 2016.

(2014) National Osteoporosis Foundation. Clinician's Guide. Available online at http://www.nof.org/wp-content/uploads/2016/02/Healthy-Bones-for-life-Clinician-Guide.pdf. Accessed June 2016.

National Osteoporosis Foundation. Overview on bone density exam/testing. Available online at https://www.nof.org/patients/diagnosis-information/bone-density-examtesting/. Accessed June 2016.

Mayo Clinic. Osteoporosis Risk Factors. Available online at http://www.mayoclinic.org/diseases-conditions/osteoporosis/basics/risk-factors/con-20019924. Accessed June 2016.

(June 2015) National Institutes of Health. Peak Bone Mass in Women. Available online at http://www.niams.nih.gov/health_info/bone/osteoporosis/bone_mass.asp Accessed June 2016.

(Nov. 28, 2013) Pisani, Paola. Screening and early diagnosis of osteoporosis through X-ray and ultrasound based techniques. World Journal of Radiology. Available online at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3856332/. Accessed June 2016.

(June 2015) United States Preventive Services Task Force. Topic Update in Progress. Available online at http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryDraft/osteoporosis-screening1. Accessed June 2016.

(2013) American College of Obstetricians and Gynecologists. Practice Bulletin on Osteoporosis. Available online at http://www.aafp.org/afp/2013/0815/p269.pdf. Accessed June 2016.

(April 1, 2016) Amgen. Romosozumab Phase 3 study. Available online at http://www.amgen.com/media/news-releases/2016/04/amgen-and-ucb-present-positive-data-at-endo-2016-comparing-romosozumab-with-teriparatide/. Accessed June 2016.

(April 4, 2016) McKee, Selina. Amgen/UCB's bone drug romosozumab shines again in PhIII. PharmaTimes Online. Available online at http://www.pharmatimes.com/news/amgenucbs_bone_drug_romosozumab_shines_again_in_phiii_1020525. Accessed June 2016.

(December 16, 2014) Talwar, S. Bone Markers in Osteoporosis. Medscape Reference. Available online at http://emedicine.medscape.com/article/128567-overview. Accessed June 2016.

Office of the Surgeon General (US). Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville (MD): 2004. 2, The Basics of Bone in Health and Disease. Available online at http://www.ncbi.nlm.nih.gov/books/NBK45504/. Accessed June 2016.

Sources Used in Previous Reviews

(2005 June, Revised). Osteoporosis Overview. NIAMS [On-line information]. Available online at http://www.niams.nih.gov/bone/hi/overview.htm.

(2005 November, Revised). Osteoporosis: The Diagnosis. NIAMS [On-line information]. Available online at http://www.niams.nih.gov/bone/hi/osteoporosis_diagnosis.htm.

Amin, S. (2004 May, Updated). Osteoporosis. American College of Rheumatology [On-line information]. Available online at http://www.rheumatology.org/public/factsheets/osteopor_new.asp?aud=pat.

(© 2006). Fast Facts. National Osteoporosis Foundation [On-line information]. Available online at http://www.nof.org/osteoporosis/diseasefacts.htm.

(2005 October 5). Bone density test: Measure your risk of osteoporosis. MayoClinic.com [On-line information]. Available online at http://www.mayoclinic.com/health/bone-density-tests/WO00024.

Sheryl L. Follin, Laura B. Hansen (Posted 05/01/2003). Current Approaches to the Prevention and Treatment of Postmenopausal Osteoporosis from American Journal of Health-System Pharmacy. Available online at http://www.medscape.com/viewarticle/453035.

WebMD A to Z Health Guide from WebMD: Medical Tests, Bone Scan (July 2006-Online information). Available online at http://www.webmd.com/hw/health_guide_atoz/hw200283.asp.

WebMD A to Z Health Guide from WebMD: Medical Tests, Bone Mineral Density (August 2006-Online information). Available online at http://www.webmd.com/hw/osteoporosis/hw3738.asp.

Vesper, H. (2005 August 10). Analytical and Preanalytical Issues in Measurement of Biochemical Bone Markers. Medscape from Laboratory Medicine [On-line information]. Available online at http://www.medscape.com/viewarticle/509097. Accessed on 12/9/07.

Srivastava, A. (2005 July 22). Clinical Use of Serum and Urine Bone Markers in the Management of Osteoporosis. Medscape Current Medical Research and Opinion [On-line information]. Available online at http://www.medscape.com/viewarticle/508542. Accessed on 12/9/07.

(2006 July). Procollagen Type 1 N-Terminal Propeptide. ARUP Technical Bulletin [On-line information]. Accessed on: 12/9/07. PDF available for download through http://wwwaruplab.com.

Cundy, T. et. al. (2007 April 13). Bone Formation Markers in Adults with Mild Osteogenesis Imperfecta. Clinical Chemistry 2007; 53:1109-1114 [On-line abstract]. Available online at http://www.clinchem.org/cgi/content/abstract/53/6/1109. Accessed on 12/9/07.

Garnero, P. et al. Evaluation of a Fully Automated Serum Assay for Total N-Terminal Propetide of Type I Collagen in Postmenopausal Osteoporosis. Clinical Chemistry 2008; 54:1, Pp. 188-196.

National Osteoporosis Foundation. Fast Facts on Osteoporosis. Available online at http://www.nof.org/osteoporosis/diseasefacts.htm. Accessed March 7, 2009.

NIAMS. Osteoporosis Overview. Available online at http://www.niams.nih.gov/Health_Info/Bone/Osteoporosis/default.asp.

Sweet MG, Sweet JM, Jeremiah MP, Galazka SS. Diagnosis and treatment of osteoporosis. Am Fam Physician. 2009 Feb 1;79(3):193-200. Available online through http://www.ncbi.nlm.nih.gov.

NATIONAL OSTEOPOROSIS FOUNDATION RELEASES NEW CLINICAL RECOMMENDATIONS FOR LOW BONE MASS AND OSTEOPOROSIS INCORPORATING ABSOLUTE FRACTURE RISK, Washington, DC (February 21, 2008). Available online at http://www.nof.org/news/pressreleases/Clinician_Guide_release.htm.

(May 15, 2006) Dolan C, et. al. Associations Between Body Composition, Anthropometry and Mortality in Women of Age 65 and Older. American Journal of Public Health 2007;97(5):913-918. Medscape Today. Available online at http://www.medscape.com/viewarticle/556519. Accessed October 2009.

Tanita. Body Composition Analyzer (FDA cleared). Available online at http://www.tanita.com/en/body-composition-analyzer/. Accessed October 2009.

National Osteoporosis Foundation. About Osteoporosis. Available online at http://www.nof.org/aboutosteoporosis/whatwomencando/introduction. Accessed September 2012.

National Osteoporosis Foundation. Why Bone Health is Important. Available online at http://www.nof.org/aboutosteoporosis/bonebasics/whybonehealth. Accessed September 2012.

National Osteoporosis Foundation on Bone Mineral Density Testing. Available online at http://www.nof.org/node/501. Accessed September 2012.

NIAMS. Osteoporosis and Related Bone Diseases. Available online at http://www.niams.nih.gov/Health_Info/Bone/. Accessed September 2012.

NIAMS. Fast Facts About Osteoporosis. Available online at http://www.niams.nih.gov/Health_Info/Bone/Osteoporosis/osteoporosis_ff.asp. Accessed September 2012.

USPSTF. Screening for Osteoporosis. Release Date: January 2011. Available online at http://www.uspreventiveservicestaskforce.org/uspstf/uspsoste.htm. Accessed September 2012.

ACOG. Osteoporosis Guidelines Issued. Bone Health Counseling Begins in Adolescence. August 21, 2012. Available online at http://www.acog.org/About_ACOG/News_Room/News_Releases/2012/Osteoporosis_Guidelines_Issued. Accessed September 2012.

Bone Markers in Osteoporosis. Medscape. Updated Jan 3, 2012. Available online at http://emedicine.medscape.com/article/128567-overview. Accessed September 2012.